Telbivudine versus lamivudine in Chinese patients with chronic hepatitis B: Results at 1 year of a randomized, double-blind trial. - Wikidata - awgldk - TriplyDB

Telbivudine versus lamivudine in Chinese patients with chronic hepatitis B: Results at 1 year of a randomized, double-blind trial.

Telbivudine versus lamivudine in Chinese patients with chronic hepatitis B: Results at 1 year of a randomized, double-blind trial.

http://www.wikidata.org/entity/Q34586082

about

Telbivudine for chronic hepatitis B Anti-HBV Drugs: Progress, Unmet Needs, and New Hope The importance of baseline viral load when assessing relative efficacy in treatment-naïve HBeAg-positive chronic hepatitis B: a systematic review and network meta-analysis Nucleoside/nucleotide analogues in the treatment of chronic hepatitis B Approved Antiviral Drugs over the Past 50 Years Potential effects of telbivudine and entecavir on renal function: a systematic review and meta-analysis Safety and efficacy of telbivudine for the treatment of chronic hepatitis B Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update.A Systematic Review of Side Effects of Nucleoside and Nucleotide Drugs Used for Treatment of Chronic Hepatitis B.Clinical impact of the early alanine amininotransferase flare during tenofovir monotherapy in treatment-naïve patients with chronic hepatitis B.Viral infection parameters not nucleoside analogue itself correlates with host immunity in nucleoside analogue therapy for chronic hepatitis B.Comparison of the efficacy of lamivudine and telbivudine in the treatment of chronic hepatitis B: a systematic review.Circulating microRNAs in hepatitis B virus-infected patients.Antiviral treatment of chronic hepatitis B virus (HBV) infections The effects of telbivudine in late pregnancy to prevent intrauterine transmission of the hepatitis B virus: a systematic review and meta-analysis.Hepatitis B virus coinfection in human immunodeficiency virus-infected patients: a review.HBsAg as an important predictor of HBeAg seroconversion following antiviral treatment for HBeAg-positive chronic hepatitis B patients Efficacy of telbivudine in Taiwanese chronic hepatitis B patients compared with GLOBE extension study and predicting treatment outcome by HBV DNA kinetics at week 24.Complementarity-determining region 3 size spectratypes of T cell receptor beta chains in CD8+ T cells following antiviral treatment of chronic hepatitis B Systematic review of the literature on comparative effectiveness of antiviral treatments for chronic hepatitis B infection.Efficacy of telbivudine on interruption of hepatitis B virus vertical transmission: a meta-analysis.Safety and efficacy of entecavir for the treatment of chronic hepatitis B.A cost-effectiveness analysis of different therapies in patients with chronic hepatitis B in Italy A comparison of treatment with adefovir and entecavir for chronic hepatitis B in China: The 2-year results of a prospective study: Adefovir versus Entercavir for Chronic Hepatitis B.Current Antiviral Therapy of Chronic Hepatitis B: Efficacy and Safety Changes in serum alanine aminotransferase levels in telbivudine versus lamivudine treatment for chronic hepatitis B: a meta-analysis.Hepatitis B virus genotypes and variants.Inhibition of viral replication downregulates CD4(+)CD25(high) regulatory T cells and programmed death-ligand 1 in chronic hepatitis B Effects of telbivudine treatment on the circulating CD4⁺ T-cell subpopulations in chronic hepatitis B patients.Therapy for HBV Infection in Hemodialysis Patients: Is it Possible?Long-Term Telbivudine Treatment Results in Resolution of Liver Inflammation and Fibrosis in Patients with Chronic Hepatitis B.Application of Bayesian Approach to Cost-Effectiveness Analysis of Antiviral Treatments in Chronic Hepatitis B.HBeAg Seroconversion in HBeAg-Positive Chronic Hepatitis B Patients Receiving Long-Term Nucleos(t)ide Analog Treatment: A Systematic Review and Network Meta-Analysis.Epidemiology study of HBV genotypes and antiviral drug resistance in multi-ethnic regions from Western China.Cost-effectiveness comparison of lamivudine plus adefovir combination treatment and nucleos(t)ide analog monotherapies in Chinese chronic hepatitis B patients Efficacy and safety of continuous 4-year telbivudine treatment in patients with chronic hepatitis B.Efficacy and Safety of Telbivudine Compared to Entecavir Among HBeAg+ Chronic Hepatitis B Patients: a Meta-Analysis Study.Telbivudine for the treatment of chronic hepatitis B in HBeAg-positive patients in China: a health economic analysis.HBeAg seroconversion as an important end point in the treatment of chronic hepatitis B.Treatment of chronic hepatitis B: focus on telbivudine.

P2860

Q24235644-CB152B6C-3D60-4731-94E3-05C3AFCFB24E Q26782742-1AAACF45-F2E1-45A9-95AB-12FCAAEFA3F7 Q27016075-8CEA030F-FBF4-45C7-BC63-7DC40B1F77E5 Q27030828-6543503A-4A9B-4311-A7D2-71D37D742AE9 Q27755387-7EBB1287-3926-485A-9C77-004A0409497C Q28074863-FB55AB68-5692-4189-9D84-959BB898F152 Q28972486-AC98B014-FBFB-42A1-9621-353F6385EA42 Q30391932-F13E4E49-937B-4895-90E7-1310147E73B1 Q33819098-2A765D88-5A9D-44D3-81CF-2EDA743FCEC5 Q33872988-D1114C20-1AED-4108-918C-26AB00916878 Q33948393-3957CD03-061A-4A8E-8E13-76D80E496CFE Q34128296-664EAFD7-273B-4021-B1AC-77B120E2A04C Q34194362-88CF8D90-E9D1-4B03-BBA9-0C8E7A0AC11B Q34223779-C841624E-83A0-4400-956E-AC9CE43AC5C6 Q34402956-D3BB5E4A-B9DF-4469-929D-DF8716CDD123 Q34405008-D10850BA-E14E-4765-99B5-1C717B4900F8 Q34505113-87C7AB87-ACA8-4FBB-A138-A1CE29486AF9 Q34509494-E8F79EF5-7093-49BA-9654-F590AE0FCECC Q34529159-8B2AA964-9422-49D0-8823-E132849DF853 Q34594403-76F1C8E2-C504-4C63-9C94-BAC556501687 Q34657327-7B39BA36-68FA-44A4-A38D-773563DBC4D3 Q35026611-B1530E60-12AE-445F-8A09-84C0A37DF340 Q35205440-6D22857B-7B10-4988-84D1-8D356F1438E3 Q35507167-0CF01167-8C0B-463F-A4C3-32165B59D802 Q35535861-2F259B70-1738-4E0D-A307-22E8E94779A6 Q35562322-CF467DD7-F71C-45BD-8188-45B657B339A7 Q35663838-B8DB5401-3868-4FE7-9784-EAE76BC9FFD2 Q35731383-8CCC3D91-7DCB-4835-846E-F43C4EEEFCAF Q35915060-EBFC99C8-7AC4-42E5-A255-8184350C4BB4 Q35920128-B5ED6524-A258-459E-B7F0-0EB5E0C1C2EA Q36067389-791628F6-8EE5-4BC1-8865-58D098A8EE78 Q36116667-423285D5-01A6-436B-B111-7C079533117B Q36255419-26386AD1-8AA2-4784-B8BE-3135B936C544 Q36324370-2FB5FE46-ACC6-4938-BD8B-9C627C1139AC Q36657542-A48025F7-366F-4F74-A3DE-62C3A4349877 Q36745002-39297BC6-3225-4D54-A17F-6CD34727C17C Q37138794-167CE660-8D21-4F2A-8021-AD3D6BE5CA66 Q37314031-72DE6A10-16DC-45FE-BBB0-EB24EE22F598 Q37356782-A63A0199-B935-4C66-979E-B89EE7123778 Q37432074-9264EBB7-77A9-4837-877D-399C9673C7E5

P2860

Telbivudine versus lamivudine in Chinese patients with chronic hepatitis B: Results at 1 year of a randomized, double-blind trial.

http://www.wikidata.org/entity/Q34586082

description

2008 nî lūn-bûn

@nan

2008 թուականի Փետրուարին հրատարակուած գիտական յօդուած

@hyw

2008 թվականի փետրվարին հրատարակված գիտական հոդված

@hy

2008年の論文

@ja

2008年論文

@yue

2008年論文

@zh-hant

2008年論文

@zh-hk

2008年論文

@zh-mo

2008年論文

@zh-tw

2008年论文

@wuu

name

Telbivudine versus lamivudine ...... andomized, double-blind trial.

@ast

Telbivudine versus lamivudine ...... andomized, double-blind trial.

@en

Telbivudine versus lamivudine ...... andomized, double-blind trial.

@nl

type

label

Telbivudine versus lamivudine ...... andomized, double-blind trial.

@ast

Telbivudine versus lamivudine ...... andomized, double-blind trial.

@en

Telbivudine versus lamivudine ...... andomized, double-blind trial.

@nl

prefLabel

Telbivudine versus lamivudine ...... andomized, double-blind trial.

@ast

Telbivudine versus lamivudine ...... andomized, double-blind trial.

@en

Telbivudine versus lamivudine ...... andomized, double-blind trial.

@nl

P1433

Q34586082-9956AFD0-99AB-445F-8611-A950DE110679

P1476

Q34586082-1A85D180-1924-498F-8899-3A7F0A9BB7E0

P2093

Q34586082-182747BA-FB03-45BC-86D8-C365B4191ECF

Q34586082-25EBBE67-E36D-43C2-8B98-BEA589E5614C

Q34586082-2846DD09-8B83-464B-836B-5B1193F513CC

Q34586082-337A1B86-7F17-41E7-9A48-43ED11F32423

Q34586082-337E1020-B1D6-4639-87CD-5848619AC80A

Q34586082-378355EA-E57A-4456-9BC6-A714E240C57D

Q34586082-3D09C41D-0221-477E-A38A-88EA3FD52AC2

Q34586082-4E3DD2A7-3C79-45BD-BE01-80B394D26E35

Q34586082-5C60B090-23F4-494C-8D3B-38C019A9B2D8

Q34586082-6BF9E4ED-16D8-4E3F-A4D4-00ECEE46D2BC

P2860

Q34586082-56C8B206-C4BB-4704-9FAD-2E53AA297842

P304

Q34586082-C5920073-BCB1-43EB-85C8-4F7CA516E50E

P31

Q34586082-102A7BF5-893B-4496-9C00-16D53ACEB651

P356

Q34586082-094BD7B2-F8FA-40D6-A719-30D5AB194D47

P407

Q34586082-944013F1-F505-4E6B-A797-375E6052B830

P433

Q34586082-12E65F05-C14B-4189-9627-D51C314DC8EF

P478

Q34586082-00384BC2-F1C7-4C19-BD1E-9F39030E1810

P577

Q34586082-9DB16127-2F6D-4EB9-B9B6-2EEE117AF9BA

P5875

Q34586082-D4035942-D5E4-45A8-89C4-DB6B4B33BB91

P698

Q34586082-B2F552C1-F0FF-41F1-A720-B93B5DA1E7D8

P356

P1433

P1476

Telbivudine versus lamivudine ...... andomized, double-blind trial.

@en

P2093

Barbara Fielman Constance

http://www.w3.org/2001/XMLSchema#string

Chengwei Chen

http://www.w3.org/2001/XMLSchema#string

Daozhen Xu

http://www.w3.org/2001/XMLSchema#string

Deming Tan

http://www.w3.org/2001/XMLSchema#string

George Chao

http://www.w3.org/2001/XMLSchema#string

George Harb

http://www.w3.org/2001/XMLSchema#string

Hong Ren

http://www.w3.org/2001/XMLSchema#string

Jiazhang Xu

http://www.w3.org/2001/XMLSchema#string

Jidong Jia

http://www.w3.org/2001/XMLSchema#string

Jinlin Hou

http://www.w3.org/2001/XMLSchema#string

P2860

A 1-year trial of telbivudine, lamivudine, and the combination in patients with hepatitis B e antigen-positive chronic hepatitis B

P304

447-454

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/HEP.22075

http://www.w3.org/2001/XMLSchema#string

P407

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

47

http://www.w3.org/2001/XMLSchema#string

P577

2008-02-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

5768930

http://www.w3.org/2001/XMLSchema#string

P698

18080339

http://www.w3.org/2001/XMLSchema#string